Overview
Allogeneic stem cell transplantation with a focus on the use of umbilical cord blood grafts; Allogenic stem cell transplantation for Sickle Cell Disease; Prevention of acute and chronic graft versus host disease; Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation.
Current Appointments & Affiliations
Professor of Medicine
·
2016 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Affiliate of the Duke Regeneration Center
·
2021 - Present
Duke Regeneration Center,
Basic Science Departments
Recent Publications
Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.
Journal Article Bone Marrow Transplant · April 12, 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item CiteOmidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program.
Journal Article Transplant Cell Ther · April 8, 2025 Omidubicel-onlv is an FDA-approved, nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB). A phase 3 study demonstrated improved hematopoietic recovery and decreased infections with omidubicel compa ... Full text Link to item CiteLong-Term Toxicity after Non-Myeloablative Conditioning Regimens Using Total Body Irradiation.
Journal Article Adv Radiat Oncol · April 2025 PURPOSE: To evaluate long-term health risks after allogeneic hematopoietic stem cell transplantation (HSCT) using non-myeloablative total body irradiation (TBI). METHODS AND MATERIALS: All adult patients undergoing non-myeloablative allogeneic HSCT using T ... Full text Link to item CiteRecent Grants
Blood and Marrow Transplant Clinical Trials Network
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2031A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)
Clinical TrialPrincipal Investigator · Awarded by Allogene Therapeutics, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Rush University ·
1992
M.D.